Targeting the body's response to low oxygen levels to treat a serious fungal infection.
Official title: Therapeutic targeting the host hypoxia-response pathway to treat Mucormycosis
Funded at University of Maryland Baltimore · NIH-11127298 · Data updated 2026-11-12
This study is looking at how we can improve treatments for Mucormycosis, a serious fungal infection that affects people with weakened immune systems, by exploring new ways to help the body respond better to the infection, and patients may have the chance to try out these new treatment methods.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | March 25, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $750,815 |
| NIH project number | 1R01AI184531-01A1 |
| Project ID | NIH-11127298 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with compromised immune systems, such as those undergoing chemotherapy, organ transplant recipients, or patients with uncontrolled diabetes.
✕Less likely to help
Patients with healthy immune systems or those not at risk for Mucormycosis may not benefit from this research.
What this research studies
This research focuses on Mucormycosis, a severe fungal infection that primarily affects individuals with weakened immune systems or underlying health conditions. The study aims to explore how manipulating the body's hypoxia-response pathway can enhance treatment effectiveness against this infection. By investigating new therapeutic approaches, the research seeks to improve patient outcomes where current antifungal treatments have limited success. Patients may be involved in trials that assess the safety and efficacy of these novel treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Mucormycosis, potentially reducing mortality rates associated with this infection.
How similar studies have gone: While the approach of targeting the hypoxia-response pathway is innovative, similar strategies in other fungal infections have shown promise, indicating potential for success in this area.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Bruno, Vincent Michael — University of Maryland Baltimore
- Study coordinator: Bruno, Vincent Michael
Related research
Other NIH-funded projects on the same topics.
-
Using MRI to measure brain oxygen levels as an early sign of small vessel disease in the brain
This study is looking at how measuring oxygen levels in the brain with MRI can help spot early signs of small vessel disease, which is linked to memory problems and dementia, especially Alzheimer's, so if you're at risk due to age or high blood pressure, you might be able to participate in MRI scans to learn more about
-
HIF-driven ways to repair damaged lungs in IPF
A doctor-researcher is testing how low-oxygen signals (HIF) could help restore healthy lung tissue in people with IPF.
-
Neonatal Brain Injury Protection with New Purine Compounds
A new medication approach using purine derivatives is being studied to protect newborn brains from injury caused by limited blood flow and oxygen during birth.
-
Aldo-keto reductase (AKR) helps brain BH4 levels after injury
This grant tests whether brain AKR enzymes can boost BH4 levels and support better brain function after hypoxia-ischemia-related injury.
-
Dual-hypoxia and proliferation PET biomarker for recurrent glioblastoma
A study using a special PET imaging approach to map oxygen-poor areas and cell growth in recurrent brain tumors to guide treatment decisions.
-
How low oxygen and genetic tweaks may repair mitochondrial problems linked to Alzheimer’s and other disorders
A Johns Hopkins-style? (Note: institution specified later) patient-facing overview: researchers will study tiny cell power stations in mitochondria to see if low-oxygen conditions and specific genetic changes can fix problems associated with Alzheimer's disease and related dementias.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.